Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial.
Conclusions -The present post-hoc analysis from TNT shows that increased TRL-C levels associate an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid-lowering with statins among CHD patients with high TRL-C. Clinical Trial Registration -URL: https://clinicaltrials.gov Unique Identifier: NCT00327691.
PMID: 29618599 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK Tags: Circulation Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Clinical Trials | Coronary Heart Disease | Genetics | Heart | Heart Attack | Heart Disease | Lipitor | Men | Statin Therapy | Stroke | Zivast